The global Rivastigmine transdermal patches market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The major factors driving the growth of this market are increasing prevalence of Alzheimer's disease and Parkinson's disease, increasing geriatric population, and rising awareness about the benefits of transdermal patches. However, high cost associated with these drugs may hamper the growth of this market in some regions.
The global Rivastigmine transdermal patches market is segmented on the basis of type (4.6mg/24hr, 9.5mg/24hr, 13.3 mg/24hr), by application (Alzheimer's Disease and Parkinson), and by region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa). The 4.6mg/24hr segment accounted for a significant share in 2017 owing to its low price as compared to other types which are priced higher due to their higher dosage strength per patch or tablet form; however it has been observed that there is an increase in demand for higher dosage strength per patch or tablet form which will lead to an increase in demand for 9-13 mg/24hr segments over time as well as increased use cases such as treatment for Parkinson's disease which will also lead to an increase in demand for 13-18 mg/24hr segments over time leading up till 2030 when all three segments are expected to be equally popular among consumers globally.
- The global population is aging and the number of people with dementia is increasing.
- Rivastigmine transdermal patches are a treatment for Alzheimer's disease, which has been shown to be effective in improving cognitive function in patients with mild to moderate Alzheimer's disease, as well as those who have had a stroke or traumatic brain injury (TBI).
- Rivastigmine transdermal patches are available by prescription only and require regular monitoring by healthcare professionals.
Industry Growth Insights published a new data on “Rivastigmine Transdermal Patches Market”. The research report is titled “Rivastigmine Transdermal Patches Market research by Types (4.6mg/24hr, 9.5mg/24hr, 13.3 mg/24hr), By Applications (Alzheimer's Disease, Parkinson, Other), By Players/Companies Novartis, Luye Pharma, ...”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Rivastigmine Transdermal Patches Market Research Report
By Type
4.6mg/24hr, 9.5mg/24hr, 13.3 mg/24hr
By Application
Alzheimer's Disease, Parkinson, Other
By Companies
Novartis, Luye Pharma, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Rivastigmine Transdermal Patches Market Report Segments:
The global Rivastigmine Transdermal Patches market is segmented on the basis of:
Types
4.6mg/24hr, 9.5mg/24hr, 13.3 mg/24hr
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Alzheimer's Disease, Parkinson, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Luye Pharma
- ...
Highlights of The Rivastigmine Transdermal Patches Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 4.6mg/24hr
- 9.5mg/24hr
- 13.3 mg/24hr
- By Application:
- Alzheimer's Disease
- Parkinson
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rivastigmine Transdermal Patches Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rivastigmine transdermal patches are a type of medication patch that is placed on the skin. Rivastigmine patches work by slowing down the nerve impulses in the brain. This helps to improve symptoms of Alzheimer's disease and other memory problems.
Some of the key players operating in the rivastigmine transdermal patches market are Novartis, Luye Pharma.
The rivastigmine transdermal patches market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Rivastigmine Transdermal Patches Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Rivastigmine Transdermal Patches Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Rivastigmine Transdermal Patches Market - Supply Chain
4.5. Global Rivastigmine Transdermal Patches Market Forecast
4.5.1. Rivastigmine Transdermal Patches Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Rivastigmine Transdermal Patches Market Size (000 Units) and Y-o-Y Growth
4.5.3. Rivastigmine Transdermal Patches Market Absolute $ Opportunity
5. Global Rivastigmine Transdermal Patches Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
5.3.1. 4.6mg/24hr
5.3.2. 9.5mg/24hr
5.3.3. 13.3 mg/24hr
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Rivastigmine Transdermal Patches Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
6.3.1. Alzheimer's Disease
6.3.2. Parkinson
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Rivastigmine Transdermal Patches Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Rivastigmine Transdermal Patches Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Rivastigmine Transdermal Patches Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Rivastigmine Transdermal Patches Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Rivastigmine Transdermal Patches Demand Share Forecast, 2019-2029
9. North America Rivastigmine Transdermal Patches Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
9.4.1. Alzheimer's Disease
9.4.2. Parkinson
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
9.7.1. 4.6mg/24hr
9.7.2. 9.5mg/24hr
9.7.3. 13.3 mg/24hr
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Rivastigmine Transdermal Patches Demand Share Forecast, 2019-2029
10. Latin America Rivastigmine Transdermal Patches Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
10.4.1. Alzheimer's Disease
10.4.2. Parkinson
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
10.7.1. 4.6mg/24hr
10.7.2. 9.5mg/24hr
10.7.3. 13.3 mg/24hr
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Rivastigmine Transdermal Patches Demand Share Forecast, 2019-2029
11. Europe Rivastigmine Transdermal Patches Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Rivastigmine Transdermal Patches Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
11.4.1. Alzheimer's Disease
11.4.2. Parkinson
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
11.7.1. 4.6mg/24hr
11.7.2. 9.5mg/24hr
11.7.3. 13.3 mg/24hr
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Rivastigmine Transdermal Patches Demand Share, 2019-2029
12. Asia Pacific Rivastigmine Transdermal Patches Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Rivastigmine Transdermal Patches Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
12.4.1. Alzheimer's Disease
12.4.2. Parkinson
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
12.7.1. 4.6mg/24hr
12.7.2. 9.5mg/24hr
12.7.3. 13.3 mg/24hr
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Rivastigmine Transdermal Patches Demand Share, 2019-2029
13. Middle East & Africa Rivastigmine Transdermal Patches Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Rivastigmine Transdermal Patches Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
13.4.1. Alzheimer's Disease
13.4.2. Parkinson
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
13.7.1. 4.6mg/24hr
13.7.2. 9.5mg/24hr
13.7.3. 13.3 mg/24hr
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Rivastigmine Transdermal Patches Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Rivastigmine Transdermal Patches Market: Market Share Analysis
14.2. Rivastigmine Transdermal Patches Distributors and Customers
14.3. Rivastigmine Transdermal Patches Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Luye Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. ...
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
